HIG BioHealth Partners (HIG), the dedicated healthcare investment affiliate of HIG Capital, has co-led a USD52 million Series B financing round for Click Therapeutics, a pioneer in the field of digital therapeutics.
The Series B financing will be used to advance clinical development and commercialisation of Click’s prescription digital therapeutics pipeline. With this financing, Alex Zisson, Managing Director of HIG BioHealth Partners will join the board of Click.
Click’s pipeline of innovative digital therapeutics spans multiple therapeutic areas, from psychiatry and chronic pain, to cardiometabolic and autoimmune disorders. In addition to its internal pipeline programs, Click has entered into landmark collaboration agreements with Otsuka Pharmaceutical to develop and commercialise a prescription digital therapeutic for treatment of Major Depressive Disorder (MDD), and with Boehringer Ingelheim to develop and commercialise a prescription-based digital therapeutic to aid in the treatment of schizophrenia.
“Closing our Series B is an important milestone for Click that will allow us to further scale our proprietary Click Neurobehavioral Intervention (CNI) Platform and fund the development of new and innovative digital therapeutics for patients in need,” says David Benshoof Klein, Co-Founder and CEO of Click. “We are excited to welcome our new investors and deepen our relationship with existing investors, all of whom share our vision of a new healthcare landscape in which prescription digital therapeutics play a prominent role alongside traditional pharmacological treatments.”
Zisson adds: “Click has one of the very best platforms in digital therapeutics, and we are excited to help the Company improve patient outcomes and lower healthcare costs.”
